Acquired immunodeficiency syndrome-related lymphoma: Clinical aspects

Seminars in Oncology

Volumn 27, Issue 4 SUPPL., 2000, Pages 442-453

  Levine, A M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER INCIDENCE; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOMA; PRIORITY JOURNAL; REMISSION; REVIEW; SURVIVAL TIME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; LYMPHOMA, AIDS-RELATED; NEOPLASM STAGING; PROGNOSIS;

EID: 0033899513     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. AIDS associated non-Hodgkin's lymphoma
2. Changing disease patterns in patients with AIDS in a referral centre in the United Kingdom: The changing face of AIDS
3. Non-Hodgkin's lymphoma among people with AIDS: Incidence, presentation, and public health burden
4. AIDS related lymphoma
5. Hodgkin's and non-Hodgkin's lympomas
6. Cancer in human immunodeficiency virus infected children: A case series from the Children's Cancer Group and the National Cancer Institute
7. Non-Hodgkin's lymphoma in HIV-positive and HIV-negative homosexual men in the San Francisco Bay area: Allergies, prior medication use, and sexual practice
8. Non-Hodgkin's lymphoma in homosexual men in the San Francisco Bay area: Occupational, chemical, and environmental exposures
9. Risk factors for non-Hodgkin's lymphomas in acquired immunodeficiency syndrome (AIDS)
10. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-Δ32 mutation
11. Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-1 infected individuals
12. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy; prospective cohort study
13. Non-Hodgkin's lymphoma and primary brain lymphoma as AIDS-defining illness in Western Europe, 1988-1997. Third AIDS Malignancy Conference, Bethesda, MD, 1999
14. AIDS-related central nervous system lymphoma: Changes of epidemiological trend and of diagnostic attitudes in the era of HAART. Third AIDS Malignancy Conference, Bethesda, MD, 1999
15. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
16. Histopathologic features of high grade non-Hodgkin's lymphoma in acquired immunodeficiency syndrome
17. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
18. Primary effusion lymphoma: A distinct clinicopathologic entity associated with the Kaposi's sarcoma associated herpes virus
19. CD30 (Ki-1) positive anaplastic large cell lymphomas in indivuduals infected with the human immunodeficiency virus
20. Update on acquired immune deficiency syndrome - United States
21. Primary central nervous system lymphoma in homosexual men. Clinical, immunologic and pathologic features
22. Primary central nervous system lymphoma in AIDS: A clinical and pathological study
23. Evolving characteristics of AIDS-related lymphoma over time: A single institution study of 369 patients. Third AIDS Malignancy Conference, Bethesda, MD, 1999
24. Primary central nervous system lymphomas: Natural history and response to radiation therapy in 55 patients with AIDS
25. Epstein Barr virus in AIDS related primary central nervous system lymphoma
26. Epstein Barr virus DNA in cerebrospinal fluid from patients with AIDS related primary lymphoma of the central nervous system
27. AIDS associated primary central nervous system lymphoma
28. Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma
29. Epstein-Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome-related primary central nervous system lymphoma
30. A comparison of imaging, clinical, and pathologic aspects of space-occupying lesions within the brain in patients with acquired immune deficiency syndrome
31. Use of CT and MR imaging to distinguish intracranial lesions and to define the need for biopsy in AIDS patients
32. FDG-PET in differentiating lymphoma from non-malignant central nervous system lesions in patients with AIDS
33. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma
34. Use of thallium-201 brain SPECT to differentiate lymphoma from toxoplasma encephalitis in AIDS patients
35. Cerebral toxoplasmosis in patients with AIDS
36. Primary central nervous system lymphoma in AIDS: Results of radiation therapy
37. Primary central nervous system lymphoma
38. Primary CNS lymphoma: Managing patients with spontaneous and AIDS-related disease
39. Antivirals induce apoptosis and tumor regression in AIDS related primary central nervous system lymphoma. Third AIDS Malignancy Conference, Bethesda, MD, 1999
40. Combination antiviral therapy for treatment of primary central nervous system lymphoma associated with the Epstein Barr virus: In vivo evaluation in an animal model. Third AIDS Malignancy Conference, Bethesda, MD, 1999
41. Non-Hodgkin's lymphoma in 90 homosexual men: Relation to generalized lymphadenopathy the acquired immunodeficiency syndrome
42. AIDS associated non-Hodgkin's lymphoma in San Francisco
43. Clinical, immunological and pathologic correlates of bone marrow involvement in 253 patients with AIDS-related lymphoma
44. Lack of association between hepatitis C infection and development of AIDS related lymphoma
45. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies
46. Low dose chemotherapy with central nervous system prophylaxis and azidothymidine maintenance in AIDS-related lymphoma: A prospective multi-institutional trial
47. Numb chin syndrome in cancer: Etiology, response to treatment, and prognostic significance
48. Epstein-Barr virus infection is predictive of central nervous system involvement in AIDS-related systemic non-Hodgkin's lymphoma
49. HIV related lympoma: Prognostic factors predictive of survival
50. Extended CSF cytarabine exposure following intrathecal administration of DTC 101
51. Age and serum LDH level are independent prognostic factors in HIV related non-Hodgkin's lymphoma: A single institution study of 96 patients
52. AIDS-related non-Hodgkin's lymphoma: Abdominal CT findings in 112 patients
53. Varied appearance of AIDS-related lymphoma in the chest
54. Gallium-67 scan for distinguishing follicular hyperplasia from other AIDS associated disease in lymph nodes
55. Whole bodypositron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography
56. Whole body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma
57. Positron emission tomography in non-Hodgkins' lymphoma: Assessment of chemotherapy with fluorodeoxyglucose
58. Leptomeningeal involvement in AIDS-lymphoma: Clinical, immunologic and pathologic features
59. Epstein-Barr virus infection is predictive of central nervous system involvement in AIDS-related systemic non-Hodgkin's lymphoma
60. Prognostic factors in the treatment of human immunodeficiency virus associated non-Hodgkin's lymphoma: Analysis of AIDS Clinical Trials Group protocol 142 - Low dose versus standard dose m-BACOD plus granulocyte-macrophage stimulating factor
61. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with HIV-related systemic non-Hodgkin's lymphoma
62. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD)
63. Low dose compared with standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection
64. Treatment of HIV related non-Hodgkin's lymphoma adapted to prognostic factors. Third National AIDS Malignancy Conference, Bethesda, 1999
65. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy
66. Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma
67. Dose adjusted EPOCH chemotherapy in previously untreated HIV-associated non-Hodgkin's lymphoma: Preliminary report of efficacy, immune reconstitution, and HIV control following therapy. Third National AIDS Malignancy Conference, Bethesda, MD, 1999
68. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency vires-associated non-Hodgkin's lymphoma
69. Phase II trial of infusional cyclophosphamide, doxorubicin and etoposide (CDE) in HIV associated non-Hodgkin's lymphoma: An Eastern Cooperative Oncology Group trial (E1494). Third AIDS Malignancy Conference, Bethesda, MD, 1999
70. Chemotherapy for HIV associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy (HAART) is not associated with excessive toxicity. Third National AIDS Malignancy Conference, Bethesda, MD, 1999
71. Multi-drug resistance (MDR-1) in newly diagnosed AIDS lymphoma. Third National AIDS Malignancy Conference, Bethesda, MD, 1999
72. Mitoguazone therapy in patients with refractory or relapsed AIDS related lymphoma: Results from a multicenter phase II trial
73. Second line chemotherapy in HIV related non-Hodgkin's lymphoma
74. Peg-L-asparaginase has activity in relapsed/refractory AIDS-related lymphomas. Third AIDS Malignancy Conference, Bethesda, MD, 1999